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A neuroendocrine role for chemerin 
in hypothalamic remodelling and 
photoperiodic control of energy 
balance
Gisela Helfer1,2, Alexander W. Ross1, Lynn M. Thomson1, Claus D. Mayer3, Patrick N. Stoney4, 
Peter J. McCaffery4 & Peter J. Morgan1
Long-term and reversible changes in body weight are typical of seasonal animals. Thyroid hormone 
(TH) and retinoic acid (RA) within the tanycytes and ependymal cells of the hypothalamus have 
been implicated in the photoperiodic response. We investigated signalling downstream of RA and 
how this links to the control of body weight and food intake in photoperiodic F344 rats. Chemerin, 
an inflammatory chemokine, with a known role in energy metabolism, was identified as a target of 
RA. Gene expression of chemerin (Rarres2) and its receptors were localised within the tanycytes and 
ependymal cells, with higher expression under long (LD) versus short (SD) photoperiod, pointing to 
a physiological role. The SD to LD transition (increased food intake) was mimicked by 2 weeks of ICV 
infusion of chemerin into rats. Chemerin also increased expression of the cytoskeletal protein vimentin, 
implicating hypothalamic remodelling in this response. By contrast, acute ICV bolus injection of 
chemerin on a 12 h:12 h photoperiod inhibited food intake and decreased body weight with associated 
changes in hypothalamic neuropeptides involved in growth and feeding after 24 hr. We describe the 
hypothalamic ventricular zone as a key site of neuroendocrine regulation, where the inflammatory 
signal, chemerin, links TH and RA signaling to hypothalamic remodeling.
The mechanistic basis of long-term food intake and body weight regulation is poorly understood1, yet it 
underpins key aspects of growth, nutrient partitioning and body composition, including adiposity. Seasonal 
(photoperiod-sensitive) animals undergo pronounced cycles of weight gain and weight loss together with asso-
ciated changes in body composition as part of their natural physiology2 and it is anticipated that studies of these 
animals will provide new perspectives on the neuroendocrine basis of long-term body weight cycling and regu-
lation even in humans3.
The remarkable cycles in long-term changes in seasonal animals are synchronised by the light:dark cycle 
(photoperiod). It is now well recognised that the hypothalamic ventricular zone (HVZ) consisting of epend-
ymal cells and tanycytes, is a key site of integration of the photoperiodic signal. Early events in the response 
involve altered thyroid hormone (TH) and retinoic acid (RA) signalling within the HVZ. The changes are driven 
by thyroid-stimulating hormone (TSH), derived from the pituitary pars tuberalis, which is released into the 
median eminence (ME) during long day photoperiod (LD) where it binds to TSH receptors on neighbouring 
ventricular ependymal cells and tanycytes lining the third ventricle2,4. TSH controls expression of type 2 deiodi-
nase and, depending on the species, type 3 deiodinase, which together regulate hypothalamic TH availability5–7. 
Hypothalamic RA synthesis and signalling is also under strong photoperiodic regulation within the HVZ8 and is 
directly regulated by TH9. It is now generally accepted that changes in hypothalamic TH levels and downstream 
RA signalling within the neuroendocrine system lead to seasonal changes in body weight, food intake and repro-
duction2,4. The big gap in our knowledge has been to understand how changes in hypothalamic TH and RA sig-
nalling link to the downstream pathways regulating energy balance in the ARC and other hypothalamic regions.
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In terms of neuroendocrine control, the HVZ (ependymal cells and tanycytes) is a relatively unexplored hypo-
thalamic region, yet recent work from divergent fields has highlighted the importance of these cells to neuroen-
docrine function10. For appetite and energy balance, it has become clear that they are a stem cell population that 
can give rise to new neurons involved in appetite regulation11–13. From the seasonal biology perspective, it is also 
evident that these cells are a key interface between external photoperiodic cues and the long-term changes in met-
abolic physiology14–17. Additionally, findings from a range of seasonal species point to a potential photoperiodic 
shift in cellular remodelling involving these cells10. In the Syrian hamster (Mesocricetus auratus), BrdU incorpo-
ration into tanycytes, as a marker for cell proliferation, is affected by photoperiod18 and equally in F344 rats and 
sheep more cells are generated in SD as compared to LD15,17. In Siberian hamsters (Phodopus sungorus) and sheep, 
adaptations of neural pathways as well as cell structure and morphological changes in the hypothalamus are also 
associated with changes in photoperiod14,16,19,20. Taken together these data suggest that structural changes within 
the hypothalamus may be at the core of the long-term effects of photoperiod on physiology, such as regulation of 
energy balance and body weight.
In this study, we investigated signalling downstream of RA in the HVZ and identified Rarres2, encoding the 
inflammatory chemokine chemerin, as a key gene expressed in tanycytes and ependymal cells of the HVZ, which 
is responsive to both photoperiod and RA. Chemerin (Rarres2), a recently discovered adipokine with numerous 
biological functions21, is the ligand for the G-protein coupled receptors Cmklr1, Gpr1 and Ccrl222. It has been 
suggested that chemerin has a biological role in obesity, because in humans serum chemerin levels correlate 
with body mass index and other obesity-related biomarkers23–27. In mice, serum chemerin levels are upregulated 
by high-fat diet feeding28 and Cmklr1 knockout mice have reduced body weight and food intake compared to 
wild-type mice independently of diet29,30. However, a central role of chemerin has not been demonstrated. In this 
study we provide the first evidence that chemerin in the HVZ plays a pivotal role in energy balance regulation.
Results
Chemerin is a downstream effector of retinoic acid in the hypothalamus. To identify genes that 
mediate the downstream effect of RA in the hypothalamus, we performed an Agilent microarray analysis cov-
ering 30003 genes on hypothalamic blocks of F344 rats administered ICV with exogenous RA. We found the 
most significant changes in genes related to inflammatory pathways (Table 1) and of these genes, a promising 
candidate was Rarres2, which encodes chemerin (1.41-fold increase, p < 0.001). Using in-situ hybridisation, we 
confirmed the microarray results and showed that Rarres2 mRNA levels were significantly increased in response 
to RA injection in the HVZ (1.50-fold, p = 0.034; Fig. 1a). Ex-vivo, real-time PCR revealed that RA also induced 
significant upregulation of Rarres2 mRNA in hypothalamic slice cultures of Sprague-Dawley rats (1.46-fold, 
p = 0.006; Fig. 1b). To determine chemerin’s candidacy as a mediator of photoperiodic responses in F344 rats, 
we next asked whether its expression was changed by photoperiod in the relevant regions of the hypothalamus. 
Rarres2 mRNA expression was significantly increased in the HVZ by 28 days exposure to LD as compared to SD 
(2.41-fold, p < 0.001; Fig. 1c) and found in the ependymal cell layer lining the third ventricle and the ME of the 
hypothalamus (Fig. 1d). Chemerin is known to bind to three G-protein coupled receptors26, Cmklr1 (ChemR23, 
DEZ), Ccrl2 and Gpr1. Like Rarres2, Cmklr1 and Ccrl2 mRNAs are also localised in the ependymal cell layer and 
ME of the hypothalamus (Fig. 1e,f), but we were unable to detect expression of Gpr1 mRNA in the hypothalamus 
of F344 rats by in-situ hybridisation (data not shown).
Long-term chemerin infusion modulates food intake. To explore whether chemerin has an impact on 
physiological function, we first tested the effect on body weight and food intake of chronic delivery of chemerin 
over 28 days into F344 rats held in SD. Given that RA levels are elevated in LD, our hypothesis was that chemerin 
would induce elevated levels of body weight and food intake in the long-term.
Initially, a range of doses (100 nmol, 1 μ mol, 10 μ mol) of human chemerin dissolved in 5 μ l saline injected ICV 
into F344 rats was tested and the strongest response was found at a concentration of 100 nmol (data not shown). 
Pathway Annot.genes Sig. genes p value*
inflammatory response 152 50 1.36 × 10−17
immune response 197 50 7.14 × 10−14
positive regulation of I-κ B kinase/NF-κ B cascade 130 33 1.03 × 10−9
antigen processing and presentation 54 21 2.41 × 10−9
antigen processing and presentation of exogenous 
peptide antigen via MHC class II 17 13 6.76 × 10
−9
chemotaxis 53 20 8.65 × 10−9
innate immune response 62 20 7.33 × 10−8
ruffle 58 19 1.26 × 10−7
immunoglobulin mediated immune response 15 11 1.34 × 10−7
Ras protein signal transduction 60 19 1.95 × 10−7
chemokine activity 39 15 4.97 × 10−7
neutrophil chemotaxis 28 13 5.27 × 10−7
Table 1.  Pathway analysis of genes found by microarray showing the strongest difference after injection 
of RA. The most significant changes were in genes related to inflammatory and immune responses. The 12 
pathways with the highest percentage of changes are shown. * p value calculated by Fisher test.
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Therefore, all subsequent experiments were performed at this concentration. Following chronic chemerin infu-
sion (100 nmol/day for 28 days), rats exhibited a period of higher food intake. 2-way ANOVA showed that there 
was a significant interaction between treatment and day (p = 0.001) and pairwise comparison revealed that rats 
infused with chemerin ate significantly more on day 12 and 15 than their saline-infused counterparts (p = 0.004 
and p = 0.030, respectively). However, the effect of chemerin on food intake was temporary and at 28 days no sig-
nificant difference was observable between the two groups (Fig. 2a). The transient increase of chemerin on food 
intake appeared to be associated with a transient effect on body weight, however, this narrowly failed to reach 
statistical significance (2-way ANOVA, p = 0.059; Fig. 2b).
In a repeat study, chemerin was infused for 14 days (100 nmol/day). Food intake resembled that of the original 
28 day experiment with significantly higher food intake in chemerin-infused rats on day 14 (p = 0.015; Fig. 2d), 
but no differences in body weight was observed in this shorter study (p = 0.636; Fig. 2e). The repeat was per-
formed to facilitate analysis of the effect of chemerin in the brain at a time point when the physiological changes 
were manifested, based on the results from the first experiment.
Chemerin treatment had no effect on paired testes weight in either experiment (28 days: p = 0.957, Fig. 2c; 14 
days: p = 0.489, Fig. 2f).
Acute impact of chemerin on physiological function. As a next step, we investigated the acute effects 
of chemerin on body weight and food intake. 100 nmol of chemerin was administered ICV at ZT3 into F344 rats 
as a bolus injection. Acute injection of chemerin had an opposite effect on physiology compared to long-term 
infusion. Pairwise comparison revealed that acute chemerin injection caused a marked reduction in body weight 
(p = 0.006; Fig. 3a). The change in body weight was accompanied by a significant decrease in food intake after 
24 hrs (p = 0.002). No difference was detected in food intake over a shorter time period (2, 4 and 6 hrs; Fig. 3b). 
Core body temperature was significantly different in chemerin-injected rats compared to saline-injected rats 
(two-way RM ANOVA, treatment x time interaction, p < 0.001). Pairwise comparison showed that the maxi-
mum difference in body temperature, with an increase of about 1.5 °C, was by 23 hrs post-injection (p < 0.001; 
Fig. 3c). However, the mean body temperature over the entire 24 hr period was not statistically different between 
treatments (t-test, p = 0.828).
Chemerin alters hypothalamic neuropeptide expression in the short-term. Next, we tested 
if chemerin was involved in the regulation of hypothalamic peptidergic modulators that play a role in growth 
Figure 1. Chemerin (Rarres2) is a photoperiod-sensitive signal downstream of retinoic acid in the 
hypothalamus. (a) Rarres2 mRNA expression in male F344 rats 24 hrs after ICV RA injection (10 μ M, n = 5) 
is significantly increased compared to vehicle treated rats (n = 6). F344 rats were acclimated in a SD (8 h:16 h) 
light:dark schedule before RA injection. (b) Rarres2 mRNA expression is also responsive to RA ex-vivo. 
Hypothalamic slices from Sprague Dawley rat pups were cultured for 4 days and then treated for 48 hrs with 1 μ 
M RA (n = 11/group) before qPCR analysis. (c) Rarres2 mRNA is significantly increased by 28 days of exposure 
to LD (16 h:8 h; n = 8) compared to SD (n = 8). (d) Rarres2 expression is localised in the ependymal cell layer 
and median eminence of the hypothalamus, the same neuroanatomical regions as its receptors (e) Cmklr1 
and (f) Ccrl2. Representative autoradiographic images are shown. Scale bar is 1.0 mm. Data presented are 
mean ± SEM, * p < 0.05, * * p < 0.01, * * * p < 0.001. LD, long day; SD, short day; RA, retinoic acid.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:26830 | DOI: 10.1038/srep26830
and feeding (Fig. 4). Hypothalamic neuropeptide gene expression was investigated in rats acutely injected with 
chemerin for 24 hrs (Fig. 4a–e) and in rats chronically infused with chemerin for 2 weeks (Fig. 4f–j). In line with 
chemerin’s potential to suppress body weight in the short-term, Ghrh and Srif mRNA expression were significantly 
lower in chemerin-injected rats than in SD-housed control rats (p = 0.005 and p = 0.012, Fig. 4a,b, respectively). 
Pomc and AgRP mRNA levels were also significantly down-regulated by acute chemerin injection (p = 0.05 and 
p = 0.032, Fig. 4c,d, respectively), while no difference was found in Npy mRNA expression (p = 0.931, Fig. 4e). 
Chronic delivery of chemerin for 2 weeks had no effect on Ghrh (p = 0.457, Fig. 4f), Srif (p = 0.544; Fig. 4g), AgRP 
(p = 0.955; Fig. 4i) and Npy (p = 0.580; Fig. 4j), but Pomc mRNA expression was significantly upregulated com-
pared to saline-infused rats (p = 0.0105, Fig. 4h).
Chemerin drives changes in hypothalamic plasticity. The next experiment was to investigate whether 
ependymal cell and tanycyte morphology was altered by chemerin. We used the intermediate filament protein 
vimentin, which shows a marked photoperiodic difference in hamsters14,20,31, as a marker for estimating hypotha-
lamic plasticity, which was defined as the capacity of the brain to adjust its cell structure and morphology16. First 
we confirmed that vimentin mRNA and protein expression also changes photoperiodically in the HVZ of F344 
rats. Vimentin mRNA was significantly up-regulated in the ependymal cell layer in LD-housed rats compared to 
their SD-housed counterparts (1.31-fold, p > 0.001; Fig. 5a). Vimentin-positive cells were found in the ependy-
mal cells and the tanycytes lining the third ventricle as well as in the ME. The most pronounced photoperiodic 
difference was found in the ependymal cell layer. While in LD, vimentin-positive cells where densely distributed 
forming long processes reaching into the medial basal hypothalamus, these were decreased or absent in SD in the 
ependymal cell layer (Fig. 5b,c). Using a fluorescence in-situ hybridisation (fISH) for Rarres2 followed by immu-
nostaining for vimentin we confirmed that Rarres2 mRNA is expressed by tanycytes. Rarres2 mRNA colocalised 
with vimentin in cells in the HVZ and ME (Fig. 5d–f).
Next, we investigated if vimentin expression changes after chemerin injection. By 24 hrs post chemerin injec-
tion, vimentin mRNA was increased by about 50% in the ependymal cell region of chemerin-injected F344 rats 
relative to controls (p = 0.0257, Fig. 5g,h), indicating that one of chemerin’s initial actions in the hypothalamus 
might be as a driver of structural remodelling of the hypothalamus.
Because the effect on the mRNA level was not maintained over the long-term (data not shown), we used 
immunohistochemistry to label ependymal cells to investigate if morphological changes were evident. In the 
control rats, little to no vimentin immunoreactivity was detected in the ependymal cells and tanycytes, with 
clearly fewer stained cells compared to chemerin-infused rats (Fig. 6a,c), similar to SD photoperiod. The 
 difference in staining was most prominent in the dorsal part of the ventricle. In chemerin-infused rats, vimentin 
immunostaining revealed intensely stained cells in the ependymal cells and in the tanycytes in ventral and dorsal 
Figure 2. Effect of chronic ICV infusion of chemerin on food intake, body weight and testicular growth. 
Ad libitum fed male F344 rats, held in a SD (8 h:16 h) light:dark schedule, received a chronic ICV infusion of 
chemerin (100 nmol/day; n = 7) or vehicle (n = 7) for 28 days (top panels; a–c) or 14 days (lower panels; d–f). 
Food intakes (a,d), body weights (b,e) and paired testes weights are shown (c,f). Data shown are mean± SEM; 
*p < 0.05, * *p < 0.01. SD, short day; chem, chemerin.
www.nature.com/scientificreports/
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regions of the third ventricle. Vimentin-positive cells extended away from the ependymal cell layer appearing 
densely distributed with longer processes (Fig. 6b,f), resembling LD conditions. Vimentin immunostaining was 
also strongly observed in the ME, but equally so in chemerin-infused and control animals (Fig. 6a,b). Glial fibril-
lary acidic protein (GFAP)-positive cells, indicative of astrocytes, were found throughout the hypothalamus with 
no apparent difference between vehicle and chemerin-infused F344 rats (Fig. 6d,g). Colocalisation of vimentin 
and GFAP showed no overlap (Fig. 6e,h).
Discussion
Previous studies have shown the importance of local synthesis of both TH and RA within the HVZ of the hypo-
thalamus to the photoperiodic response2,4 and recent work has revealed that TH regulates the expression of 
Raldh1 suggesting that TH drives the photoperiodic response at least in part through RA signalling9 (Fig. 7). In 
this study, the expression of the inflammatory chemokine chemerin and its receptors, Cmklr1 and Ccrl2, were 
localised to the HVZ and it was shown that chemerin (Rarres2) gene expression was responsive to photoperiod 
and RA. Given that chemerin infused ICV into SD rats can partially and transiently mimic the SD to LD transi-
tion in terms of food intake, these findings show that chemerin, and intermediate filament protein, vimentin, are 
downstream elements of the hypothalamic RA pathway. Moreover, these data provide the first plausible evidence 
to link photoperiod to the long-term regulation of energy balance and body weight through potential remodelling 
of the hypothalamus. The basis for this conclusion is that previous studies in Siberian hamster have shown how 
cells immunopositive for vimentin project radially from tanycytes into the medial basal hypothalamus, although 
the extent of the radial projections are photoperiod-dependent, with long projections under LD, which decrease 
or disappear under SD20. Other work undertaken in hamsters and sheep has also shown morphological changes 
in the hypothalamus that are associated with changes in photoperiod14,16,18,19. Thus, the increased vimentin 
immunolabelling of projections from the tanycytes and ependymal cells of the HVZ of SD-housed F344 rats in 
response to 2 week infusion of chemerin mimics a LD response. From this it seems reasonable to conclude that 
the changes in vimentin immunoreactive projections from the tanycyte and ependymal cells contribute to the 
Figure 3. Effect of acute ICV injection of chemerin on body weight, food intake and body temperature. Ad 
libitum fed F344 rats held in a 12 h:12 h light: dark schedule received an ICV injection of 100 nmol chemerin 
(n = 4) or vehicle (n = 4) at ZT3. 24 hrs after the injection (a) body weight and (b) food intake was significantly 
decreased compared to saline-injected rats. (c) Core body temperature was significantly different in chemerin-
injected rats compared to saline-injected rats. Data shown are mean ± SEM, * p < 0.05, * * p < 0.01, * * * p < 0.01. 
Chem, chemerin.
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mechanism involved in the neuroendocrine changes in physiology, such as food intake and body weight. It also 
provides further evidence to support the emerging importance of the HVZ as a key site of regulation within the 
neuroendocrine hypothalamus (Fig. 7).
Chemerin is an adipokine encoded by the gene Rarres2, originally identified by its RA responsiveness in 
psoriatic skin lesions21. It has since been found to have a number of potential roles including chemotactic, adi-
pokine, autocrine/paracrine, adipogenic, angiogenic and reproductive functions22,26. Nonetheless, its role in the 
regulation of energy metabolism and metabolic syndrome23,26,28,29,32 makes it a promising candidate relevant to 
our studies of long-term energy balance regulation.
In this study we show that chemerin induces a transient increase in food intake, but this effect is not pro-
longed. The most likely explanation for this transient effect is that constant infusion of chemerin ICV may only 
poorly mimic the pattern of secretion and bioavailability of endogenous chemerin over longer timeframes. For 
example, it is known that chemerin must be enzymatically cleaved to become bioactive and a number of isoforms 
of chemerin with varying receptor affinity have been detected in different tissues26. Secondly, prolonged exposure 
to high levels of chemerin might cause desensitisation of its receptors and/or cause habituation. Nevertheless, 
while chemerin partially mimics the photoperiodic SD to LD transition when infused into the third ventricle 
of animals in SD, a very different response was observed when given as an acute bolus injection ICV into rats 
on a 12 h:12 h light:dark schedule, a photoperiod that maintains rats in a LD state33. Here, both food intake and 
body weight, were suppressed within 24 hrs. This indicates an anorectic effect, which differs to a previous report 
where chemerin was injected directly into the hypothalamus and yet no effect on food intake and body weight 
was observed34. The difference in response may be explained by the different sites of delivery (ARC tissue vs ICV) 
and doses used.
The apparent bimodal response to chemerin seen in this study, when given either acutely or chronically, is 
also most likely related to the route, mode of delivery and/or dose used, which would impact on chemerin’s bio-
availablity or receptor sensitivity as suggested above. However another factor could be photoperiod. The chronic 
infusion study was designed to replicate the SD to LD transition. Based on levels of chemerin gene expression 
in the hypothalamus, it was predicted that hypothalamic chemerin levels would be considerably lower under SD 
Figure 4. Effect of chemerin administration on gene expression of growth and feeding-related 
hypothalamic peptides. (a) Ghrh, (b) Srif, (c) Pomc and (d) AgRP mRNA levels were significantly 
downregulated 24 hrs after a bolus ICV injection of chemerin (100 nmol; n = 4) compared to vehicle injection 
(n = 4) whereas (e) Npy mRNA expression was unaffected. (f–j) Chronic infusion of chemerin (100 nmol/
day/14 days, n = 7) had no effect on (f) Ghrh, (g) Srif, (i) AgRP and (j) Npy mRNA levels compared to vehicle 
infusion (n = 7), but (h) Pomc mRNA expression was significantly upregulated. Data shown are mean ± SEM 
and presented relative to SD; * p < 0.05, * * p < 0.01. Chem, chemerin.
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than LD. On this basis infusion of chemerin into rats in SD would be against a low background level of chemerin 
in the hypothalamus. Infusion of chemerin into LD animals was not tested, as it was anticipated that this would 
be without effect. However, it is possible that the effect of acute administration of chemerin to rats on 12 h:12 h 
photoperiod reflects a true LD response, where chemerin becomes inhibitory when given at high dose to rats with 
already high endogenous levels of chemerin. In that regard it is noteworthy that, in another study, high doses of 
chemerin injected intra-peritoneally for 17 days into Wistar rat on 12 h:12 h photoperiod suppressed both food 
intake and body weight35.
Chemerin exerts its effects by binding to and activating the G protein-coupled receptor Cmklr1 but it also 
serves as a ligand for the chemokine receptor-like protein Ccrl2 and the G protein-coupled receptor Gpr126. Both, 
Cmklr1 and Ccrl2 mRNAs were expressed in the ependymal cell layer of the HVZ, closely matching the distri-
bution of Rarres2 mRNA. Ccrl2 is a non-signalling receptor that binds chemerin to increase its concentration28 
therefore, since chemerin is in part locally produced, it might function to amplify the hypothalamic activity of 
chemerin. Little is known about Gpr1, although it has recently been associated with high-fat diet induced glucose 
intolerance36. By in-situ hybridisation, we could not detect Gpr1 mRNA expression in the relevant hypothalamic 
regions associated with energy balance control. Since loss of Gpr1 does not affect body weight in Gpr1 knockout 
mice on a chow diet36, the neuroendocrine effects of chemerin are likely to be predominantly regulated via the 
chemerin/Cmklr1 axis.
Chemerin’s role in the photoperiod response, and thereby its potential link to energy balance, was discovered 
following acute injection of RA into the third ventricle of F344 rats in SD, which increased the expression of 
chemerin, consistent with higher production of chemerin under LD. The acute injection of RA into the third ven-
tricle of F344 rats on SD revealed changes not only in chemerin, but also altered expression, within the hypothal-
amus, of a number of other genes associated with inflammatory and immune responses (Table 1). Several studies 
have implicated inflammation in key hypothalamic areas in the control of body weight, with the inflammation 
involved being largely a pathophysiological consequence of overnutrition37,38. In addition, it has been suggested 
that this may be a cause of the increase in the biologically defended level of body weight that underlies obesity38. 
The finding that chemerin can alter long-term food intake in the seasonal F344 rats provides an example of a 
physiological, rather than pathophysiological, role for an inflammatory signal in the neuroendocrine control of 
Figure 5. Chemerin drives hypothalamic remodelling. (a) Vimentin mRNA in the ependymal cell layer is 
significantly increased by 28 days of exposure to LD (n = 8) compared to SD (n = 8). (b) Vimentin immunostaining 
is reduced in the dorsal part of the ependymal cell layer in F344 rats held in SD (8 h:16 h) compared to (c) F344 rats 
held in LD (16 h:8 h) photoperiod for 28 days (magnification 100x; Vimentin in red overlaid with Dapi in blue). 
(d) Rarres2 mRNA (green) and (e) Vimentin immunolabelling (red) are (f) coexpressed in the ME and the EPL 
(examples indicated by white arrowheads; magnification 400x). (g) Vimentin mRNA is upregulated in F344 rats 
24 hrs after a bolus ICV injection of chemerin (100 nmol; n = 4) relative to controls (n = 4). (h) Vimentin mRNA 
expression in the tanycytes and ependymal cells lining the third ventricle of the hypothalamus in vehicle- and 
chemerin-injected F344 rats. Representative images are shown. Data presented are mean ± SEM, * p < 0.05,  
* * * p < 0.001; 3 V, third ventricle; chem, chemerin; EPL, ependymal cell layer; ME, median eminence; LD, long day; 
SD, short day.
www.nature.com/scientificreports/
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appetite and energy balance. In this context, it will be interesting to study if the other genes, uncovered by the 
microarray analysis, are also involved in the photoperiod response and whether their effect is a physiological 
rather than a pathophysiological response.
Figure 6. Vimentin and glial fibrillary acidic protein (GFAP) immunostaining in the rat hypothalamus. 
F344 rats held in a SD (8 h:16 h) light:dark schedule were infused with (a) vehicle (n = 5) or (b) 100 nmol/day/14 
days chemerin (n = 5). (a,b) Merged overview of the relevant hypothalamic region with vimentin in red, GFAP 
in green and nuclear counterstaining with DAPI in blue (magnification 100X). (c–h) Representative images 
of inset outlined in white in (a,b) showing the EPL lining the 3 V of the hypothalamus (magnification 400X). 
Vimentin immunolabelling (red) is lower in the dorsal part of the ependymal region of vehicle (c) compared 
to chemerin infused rats (f). GFAP-positive cells (green) are found throughout the hypothalamus with no 
difference between (d) vehicle and (g) chemerin infused rats. (e,h) Colocalisation of vimentin (red) and GFAP 
(green) shows that there is no overlap. EPL: ependymal cell layer; 3 V: third ventricle; ME: median eminence. 
Examples of positive cells are indicated by white arrowheads.
Figure 7. Hypothetical model of how chemerin might contribute to morphological changes in the 
hypothalamus. (a) During long day (LD) photoperiod, thyroid-stimulating hormone (TSH) is released from 
the pars tuberalis (PT) into the median eminence (ME) where it binds to TSH receptors (TSHR) on tanycytes 
lining the third ventricle (3 V). In LD, densely distributed tanycytes form long projections into the medial 
basal hypothalamus, which decrease or disappear in short day (SD) photoperiod. (b) TSH binds to TSHR on 
tanycytes and this increases Dio2 expression and decreases Dio3 expression. Dio2 converts thyroid hormone 
T4 into the more active form T3, which is then inactivated by Dio3. In LD, rising levels of T3 upregulate Raldh1 
expression which synthesises retinoic acid (RA). RA enters the nucleus where binding to retinoic acid receptors 
(RAR/RXR) leads to transcription of Rarres2 and other target genes. Chemerin (Rarres2) binds to its receptors 
(Cmklr1) possibly on the same or on neighbouring cells. An increase in chemerin results in an increase in 
Vimentin in the cell and the tanycyte extends away from the ependymal cell layer (EPL) into the hypothalamus 
forming long projections during this process.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:26830 | DOI: 10.1038/srep26830
It is well established that feeding behaviour is under the control of hypothalamic circuits39. Despite this, 
chemerin does not seem to act directly through known neuroendocrine energy balance and growth pathways to 
exert its effects. Following acute bolus injection of chemerin into rats in 12 h:12 h photoperiod, food intake and 
body weight are reduced. Yet gene expression in the ARC for both orexigenic (AgRP) and anorexigenic (Pomc), 
as well as stimulators (Ghrh) and inhibitors (Srif) of growth, are all reduced. This is against expectation, as these 
opposing signals are typically reciprocally regulated39. Similarly, in response to long-term chemerin-infusion into 
SD rats, the pattern of gene expression of hypothalamic neuropeptides did not follow simple prediction according 
the status of energy balance. Thus consistent with previous studies of energy balance in seasonal animal models, 
expression of hypothalamic orexigenic and anorexigenic genes is not a straightforward reflection of food intake 
or body weight status of the animal40,41. However, this is not something restricted to seasonal animal models, as 
in mice with a genetic ablation of Cmklr1, hypothalamic AgRP, Pomc or Npy expression also do not correlate 
with the levels of food intake29. Therefore, it seems that the long-term effect of chemerin on food intake and body 
weight is not a direct or simple correlative neuroendocrine relationship with known appetite and energy balance 
pathways and so other hypothalamic mechanisms must be involved in the effects of chemerin on food intake and 
body weight. A more tantalizing possibility is for chemerin to exert its effects through cellular remodelling. The 
effect of chemerin on vimentin mRNA levels within 24 hrs and vimentin immunolabelling over 2 weeks within the 
cells of the HVZ lends credence to such an idea. From the seasonal biology perspective, this study provides fur-
ther evidence for the view that photoperiod dependent changes in tanycytes and ependymal cells drive long-term 
changes in metabolic physiology10,42.
In conclusion, we have identified a novel signalling cascade, downstream of TH and RA, in the hypothalamus 
of seasonal rats. Specifically we show that the inflammatory gene, Rarres2, encoding the chemokine chemerin, 
has restricted expression in the HVZ (both tanycytes and ependymal cells) and it has a role in the regulation of 
food intake and body weight in seasonal animals. This involves chemerin-induced changes in vimentin expres-
sion showing that the seasonal neuroendocrine response involves hypothalamic remodelling. Given that the com-
ponents of the signalling pathway described in this study are also expressed in the HVZ of non-seasonal animals, 
it is likely that these findings will have relevance to the regulation of food intake and energy balance in mammals 
more widely.
Methods
Animals. Animal experiments were approved by the ethics committee at the Rowett Institute of Nutrition and 
Health and carried out in accordance with UK Home Office guidelines, licensed under the Animals (Scientific 
Procedures) Act, 1986 (project licence numbers PPL60/3615 and PPL60/4282).
In-vivo experiments used male F344/NHsd rats from Harlan Sprague-Dawley Inc. Rats were acclimatised for 
10–14 days before they were randomly assigned to weight-matched experimental groups. Ex-vivo experiments 
used male Sprague Dawley rat pubs bred in the animal facility at the University of Aberdeen.
Besides from photoperiod (SD 8 h:16 h; LD 16 h:12 h) changes, rats were kept under the same standard con-
ditions (ambient temperature: 21 ± 2 °C; relative humidity: 55 ± 10%; average light intensity: 150 lux). Rats were 
housed in standard rat cages type RC2/f with G6 woodchip bedding and shredded paper and a red plastic tunnel 
for enrichment. Rats had unrestricted access to food (CRM(P) Rat and Mouse Breeder and Grower, standard 
pelleted diet, Special Diet Services) and water. For central administration of substances, cannulae were stereotax-
ically implanted into the ventricle as described previously7.
Before killing, rats were assigned random numbers to ensure blind analysis for the experimental conditions. 
For in-situ hybridisation studies, rats were killed with isoflurane inhalation followed by decapitation and for 
immunohistochemistry studies, rats were killed with intraperitoneal injections of Pentoject (Animalcare Limited) 
followed by transcardially perfusion with 4% paraformaldehyde in 01.M phosphate buffer (PB). For all experi-
ments killing took place at around zeitgeber time (ZT) 3.
Retinoic acid (RA) injections. F344 rats were group housed and exposed to SD during acclimatisation. 
Rats (weight range 201.7–229.6 g) were surgically prepared and intracerebroventricular injections (ICV) were 
performed as described previously7. Stereotaxic coordinates to reach the third ventricle of the hypothalamus were 
0.8 mm posterior to the bregma line on the mid-sagittal line, 6.5 mm below the outer surface of the scull. After 
surgery, rats were pair-housed. Cannula placement was confirmed by a positive dipsogenic response to 100 ng 
of angiotensin (Sigma-Aldrich) in 5 μ l of 0.9% saline. 7 days later, rats that tested positive to angiotensin, were 
injected with 5 μ l of 10−4 M all-trans RA in 10% DMSO in 0.9% saline (n = 4) or vehicle (n = 4) at ZT3. 24 hrs after 
RA injections, rats were killed. This experiment was repeated to provide tissue for in-situ hybridisation analysis 
(repeat study weight range 185.3–212.2 g). Here, rats were injected with 5 μ l of 10−5 M all-trans RA in 10% DMSO 
in 0.9% saline (n = 5) or vehicle (n = 6).
Chemerin injections. F344 rats were exposed to a 12 h:12 h schedule and pair-housed until ICV injections. 
The surgery weight of the rats was 190.4–211.7 g. Initially, a chemerin dose-response experiment was performed. 
Rats were injected with 100 nmol (n = 4), 1μ mol (n = 5) or 10 μ mol (n = 4) human chemerin (Cell guidance sys-
tems) in 0.9% saline or vehicle (n = 4) at ZT3. After chemerin injections rats were single housed and presented 
with a preweighed amount of chow and food intake was measured after 2, 4, 6 and 24 hrs. Body weight was meas-
ured before ICV injection and 24 hrs afterwards. Core body temperature was measured remotely using i-button® 
devices (Maxim Integrated Products) implanted into the peritoneum during ICV cannulation. Rats were killed 
24 hrs after chemerin injection at ZT3.
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Chemerin infusion. F344 rats were group housed in SD from arrival. After acclimatisation, brain infusion 
cannulae were implanted into the third ventricle of the rats (weight range of 227.5–253.2 g). Based on the results 
of the dose-response experiment, 100 nmol/day of human chemerin in 0.9% saline (n = 7) or vehicle (n = 7) was 
constantly delivered via subcutaneously implanted osmotic minipumps (Alzet; model 1004, flow rate 0.11 μ l/hr) 
connected to the ICV cannula over a 28 day period. For accurate body weight and food intake measurements (at 
least 3× weekly), rats were housed singly after surgery. Cannulae placement was verified at the end of the exper-
iment by dye administration. After 28 days, rats were killed, brains collected and paired testes weight recorded.
The study was repeated with an infusion period of 14 days. The weight range of the repeat study was 
232.6–254.9 g. Alzet osmotic minipumps model 1002, flow rate 0.25 μ l/hr were used. 14 days after surgery, rats 
were killed and brains collected for in-situ hybridisation (n = 7/group) and immunohistochemistry (n = 5/group).
Photoperiod study. After acclimatisation in 12 h:12 h, F344 rats (weight range of 117.1–142.7 g) were ran-
domly divided into two weight matched groups (n = 8/group) and transferred to either SD or LD. After 28 days, 
single-housed rats were killed at ZT3.
Microarray analysis. Total RNA was extracted from 60 to 80 mg of frozen hypothalamic tissue blocks using 
an RNeasy Mini Kit with on-column DNase treatment (Qiagen). RNA quality was measured using a Bioanalyzer 
2100 (Agilent Technologies). For microarray (Agilent-028279 SurePrint G3 Rat GE 8 × 60 K Microarray, Agilent 
Technologies), RA injected samples (n = 4) and control samples (n = 4) were analysed with dye-swap. Labelling 
and hybridisation of the RNA samples was outsourced to the Genomics Laboratories at the Rowett Institute 
of Nutrition and Health. Briefly, 100 ng of total RNA was used with the Low Input Quick Amp Labelling kit, 
two-colour (Agilent Technologies). RNA was amplified in two steps to cRNA, incorporating Cy-3 and Cy-5 dyes, 
and was purified with RNeasy mini spin columns (Qiagen). For hybridisation, the Gene Expression Hybridisation 
Kit (Agilent Technologies) was used. Labelled cRNA was hybridised to SurePrint G3 Rat GE 8 × 60 K microarray 
slides (Agilent Technologies) rotating at 65 °C for 17 hrs. The arrays were washed using the Gene Expression 
Wash Buffer Kit (Agilent Technologies) and then scanned on a SureScan High Resolution Scanner (Agilent 
Technologies).
Ex-vivo hypothalamic slice cultures and qPCR. Ex-vivo hypothalamic slice cultures were set up as pre-
viously described9. Slices were treated for 48 hrs with 1 μ M RA or an equivalent concentration of DMSO (0.1%) 
diluted in culture medium. Following treatment, total RNA was extracted from slices using a Qiagen RNeasy 
RNA purification kit. cDNA was synthesized from 500 ng total RNA using a High Capacity RNA-to-cDNA 
Master Mix (Applied Biosystems). qPCR reactions were set up using SensiMix SYBR master mix (Bioline) and 
run on a Roche LightCycler 480. Primer sequences for Rarres2 were F-CGGACATACACGGGACAGAGCTTGA 
and R-CAGCTGAGAAGAACAGGTCATCAGCAC and for Actb were F-CCACACCCGCCACCAGTTCG and 
R-TACAGCCCGGGGAGCATCGT. Rarres2 expression was normalised to Actb levels. Standard curves and blank 
controls were run for both sets of primers.
In-situ hybridisation. F344 rat hypothalamus coronal sections were cut and in-situ hybridisation 
was performed as described previously40. Riboprobe templates for Rarres2, Cmklr1, Gpr1 and vimen-
tin were amplified from rat hypothalamic cDNA and Ccrl2 from rat muscle cDNA. Primers for Rarres2 were 
F-TGGGCACAGCGGACATACACG and R-ACCATCCGGCCTAGAACTTTACCC; for Cmklr1 were 
F-CGGGAAAGCCATGTGCAAGATTAG and R-AGAGGAAGCGGGTGACGGTGAC; for Gpr1 were 
F-CGGGAAAGCCATGTGCAAGATTAG and R-AGAGGAAGCGGGTGACGGTGAC; for Ccrl2 were 
F-TTGCCCGAAGCTGTGTTTTACGAG and R-GAGGAGCGGGTTGACACAGCAGT and for Vimentin 
were F-AAGGCCCGTGTCGAGGTGGAGAG and R-TGGCGCAGGGCATCGTTCTTC. Rarres2, Grp1, Ccrl2 
and vimentin were cloned into Strata Clone Blunt PCR Cloning Vector (Stratagene), Cmklr1 was cloned into 
pCR4 Blunt TOPO vector (Invitrogen). Riboprobe templates were prepared as described earlier for growth 
hormone-releasing hormone (Ghrh) and somatostatin (Srif)40, POMC and AgRP43 and NPY44. 35S-labelled anti-
sense riboprobes were generated from ~150 ng of amplified inserts by T3 or T7 RNA polymerase as appropriate.
Immunohistochemistry. Brains were removed from perfused F344 rats, post-fixed overnight in 4% 
paraformaldehyde/0.1 M PB, cryoprotected with 30% sucrose/PB before snap frozen in isopentane on dry ice 
and stored at −70 °C. 30 μ m thick coronal brain sections were cut on a cryostat, mounted on Superfrost® Plus 
slides (Thermo Fisher Scientific) and stored in PBS/0.02% NaN3 at 4 °C. Immunohistochemistry was carried out 
using standard protocols. Briefly, slides were washed in 1xTBS, blocked in 5% bovine serum albumin/TBS/0.5% 
Tween 20 for 1 hr and incubated in primary antibodies, chicken anti-vimentin (1:1000; Millipore) and rabbit 
anti-glial fibrillary acidic protein (GFAP; 1:1000, Millipore) at 4 °C overnight. Immunoreactivity was visualised 
using secondary antibodies conjugated to fluorescent dyes (anti-chicken IgY, 1:200, R&D Systems and Alexa 
Fluor® 488, anti-rabbit IgG, 1:200, Molecular Probes). A nuclear stain was performed by mounting the slides with 
Vectashield® Mounting Medium with DAPI (Vector Laboratories).
Combined in-situ hybridisation and immunohistochemistry. Rarres2 riboprobes were DIG labelled 
by incubating 100 ng PCR amplified template for 2 hrs at 37 °C, followed by DNase RQ1 (Promega) incubation for 
15 min at 37 °C. The riboprobe was purified using a ProbeQuant G50 column (Amersham). Labelling efficiency 
was tested by membrane dot-blotting and processing with anti-DIG-POD Fab fragments and DAB substrate 
(Roche Diagnostics). For in-situ hybridisation, slides were prepared as described. Prior to primary antibody 
incubation, slides were treated with 0.3% H2O2 before being blocked with 2% TSA detection system blocking 
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reagent (Molecular Probes), followed by Streptavidin/Biotin blocking reagent (Vector labs). Slides were incu-
bated in anti-DIG-POD fab fragments in 2% TSA detection system blocking reagent (1 in 100) overnight at 
4 °C in a humidity chamber, then washed 3× for 5 min in 100 mM Tris/HCl, 150 mM NaCl, 0.3% Tween-20. 
Slides were incubated in Tyramide 488 (Molecular Probes) for 2 hrs in the dark and then washed 3× for 5 min in 
100 mM Tris/HCl, 150 mM NaCl, 0.3% Tween-20. Slides were subsequently processed for detection of Vimentin 
immuno-reactivity following the protocol described above.
Statistics. Microarray data were analysed within the statistical programming environment R (version 3.02) 
using the Bioconductor library limma (3.18.9)45. Loess normalisation was used to eliminate intensity depending 
dye-effects and the normalised data were analysed on a log 2-scale. Identical probes represented by the same 
oligo were averaged within arrays. Comparisons between RA treatment and controls where conducted by the 
limma-specific moderated t-test which borrows information across probes to stabilize the estimation of standard 
errors46. Dye-swaps were used as a blocking variable in this analysis to account for the re-use of the same samples 
with changed Cy3-Cy5 setting. This analysis provides a p-value and an average log 2-fold change for each pair-
wise comparison of interest. For pathway analysis, the Gene Ontology (GO) database was used to find groups of 
genes with similar functions. The number of genes whose annotation corresponded to a GO term was calculated 
as well as the number of differentially expressed genes among them if their p-value was below 0.01. Fisher’s exact 
test was used to test whether the number of differential genes within a GO term exceeded what could be expected 
by chance, which yields a p-value on GO term/pathway level. Data sets are accessible at the Gene Expression 
Omnibus website [GSE65300].
All other data were analysed by a two-tailed Student’s t-test, one-way ANOVA or two-way RM ANOVA (treat-
ment group x time interaction) followed by a Tukey’s post-hoc test using Sigma Plot statistical software. The 
results are presented as means ± SEM and differences were considered significant if p < 0.05.
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